Triple-negative breast cancer vaccine shows promise in early clinical trialTriple-negative breast cancer vaccine shows promise in early clinical trial
When Chase Johnson was 31, her dog began acting strange.
Triple-negative breast cancer vaccine shows promise in early clinical trialTriple-negative breast cancer vaccine shows promise in early clinical trial
When Chase Johnson was 31, her dog began acting strange.
Imaging study solves a long-standing gap in metastatic breast cancer research and careImaging study solves a long-standing gap in metastatic breast cancer research and care
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones.
Imaging study solves a long-standing gap in metastatic breast cancer research and careImaging study solves a long-standing gap in metastatic breast cancer research and care
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones.
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes PatientsGLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
(MedPage Today) — GLP-1 receptor agonists were tied to a lower risk of developing epilepsy in adults with type 2 diabetes, a large U.S. study showed. Compared with DPP-4 inhibitors, GLP-1 receptor agonist use was associated with a 16% lower risk… (MedPage Today) — GLP-1 receptor agonists were tied to a lower risk of Read More
ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer TrialADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial
(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer…
Triplet Delays Breast Cancer Progression in First-Line Maintenance SettingTriplet Delays Breast Cancer Progression in First-Line Maintenance Setting
(MedPage Today) — SAN ANTONIO — Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) significantly improved progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer…
Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trialSentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 Phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancerBreast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the Phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Preoperative radiation may improve antitumor immune response in most common form of breast cancerPreoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of a Phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.